Kantarjian et al53 assessed the efficacy and protection of dasatinib, as as opposed with imatinib, for the initial-line therapy of CML-CP. 5 hundred and nineteen patients with recently diagnosed CML-CP were randomly assigned to receive dasatinib at a dose of 100 mg once every day (259 individuals) or imatinib at https://hayleyv009rja0.westexwiki.com/user